PPIDT00279
Drug Information
| Name | Daratumumab |
|---|---|
| Sequence | EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB09331 |
| Type | biotech |
| Indication | Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma.[L13290] It is available as a combination product with [hyaluronidase] for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.[L13296] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
1800 MG
|
| Injection, solution, concentrate | Intravenous |
100 mg/5mL
|
| Injection, solution, concentrate | Intravenous |
20 mg/1ml
|
| Injection, solution, concentrate | Intravenous |
20 MG/ML
|
| Injection, solution, concentrate | Intravenous; Parenteral |
20 MG/ML
|
| Solution | Intravenous |
100 mg / 5 mL
|
| Solution | Intravenous |
400 mg / 20 mL
|
| Injection, solution, concentrate | — |
100 mg/5ml
|
| Solution, concentrate | Intravenous |
20 mg
|
| Solution, concentrate | Intravenous |
2000000 mg
|
| Injection, solution | Intravenous |
20 mg/mL
|
| Injection, solution, concentrate | — |
400 mg/20ml
|
| Solution | Intravenous |
20 mg/mL
|
| Injection | Subcutaneous |
|
| Solution | Subcutaneous |
1800 mg / 15 mL
|
| Injection, solution | Subcutaneous |
1800 mg/15mL
|
| Solution | Subcutaneous |
120 mg
|
| Solution | Subcutaneous |
12000000 mg
|